Fundraising FoxAxon Therapies
New York, US · Founded 2014 · Delaware corporation · 5 known investors
Find your way into Axon Therapies
Sign up to see every warm intro you have to Axon Therapies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Axon Therapies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF). Its Axon Ablation Catheter is used in an outpatient procedure to block nerve signals and normalize volume balance.
Founders & leadership
Axon Therapies was founded in 2014 by Howard R. Levin and Mark Gelfand.
Board
Investors · 5
How we know: board seat on SEC Form D · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$74.8M disclosed across 5 rounds · 2016–2025
▶$7.5MraisedFeb 2019 · 10 investors · Other TechnologyRule 506(b)
- Mitchell S. BloomExecutive Officer
- Steven HochbergDirector
- Paul LaVioletteDirector
- Mark GelfandExecutive Officer, Director
- Howard R. LevinExecutive Officer, Director
- Imran EbaDirector
- Andrew ElBardissiDirector
- Offering amount
- $15M
- Amount sold
- $7.5M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1.3MraisedJun 2017 · 7 investors · Other TechnologyRule 506(b)
- Mark GelfandExecutive Officer
- Howard R. LevinExecutive Officer, Director
- Mitchell S. BloomExecutive Officer
- Paul LaVioletteDirector
- Offering amount
- $2M
- Amount sold
- $1.3M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$2MraisedApr 2016 · 1 investors · Other TechnologyRule 506(b)
- Paul LaVioletteDirector
- Howard R. LevinExecutive Officer, Director
- Mark GelfandExecutive Officer
- Mitchell S. BloomExecutive Officer
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Axon Therapies.
In the news
Frequently asked questions
- What does Axon Therapies do?
- Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF). Its Axon Ablation Catheter is used in an outpatient procedure to block nerve signals and normalize volume balance.
- Who founded Axon Therapies?
- Axon Therapies was founded by Howard R. Levin, Mark Gelfand in 2014.
- Who are Axon Therapies's investors?
- Axon Therapies's investors include Star51 Capital, Action Potential Venture Capital Ltd., Deerfield Management Company, Earlybird Venture Capital, SV Health Investors.
- How much funding has Axon Therapies raised?
- Axon Therapies has disclosed $74.8M raised across 5 rounds.
- Where is Axon Therapies headquartered?
- Axon Therapies is headquartered in New York, US.